48 results on '"Colecchia, A."'
Search Results
2. PD34-10 FIRST RESULTS OF NURE-COMBO: a PHASE 2 STUDY OF NEOADJUVANT NIVOLUMAB (NIVO) AND NAB-PACLITAXEL (ABX) FOLLOWED BY POSTSURGICAL ADJUVANT NIVO IN PATIENTS (PTS) WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC)
3. MP71-07 THE IMPACT OF CENTRALIZED UROPATHOLOGY REVIEW IN THE MANAGEMENT OF BLADDER CANCER PATIENTS AT THE TIME OF TRANSURETHRAL RESECTION OF THE BLADDER
4. MP58-08 CONCORDANCE OF RENAL SINUS OR CALYCES INVASION BETWEEN PREOPERATIVE IMAGING AND FINAL PATHOLOGY AFTER SURGERY FOR KIDNEY CANCER
5. PD36-04 UTILITY OF PRE- AND POST-PEMBROLIZUMAB VESICAL IMAGING – REPORTING AND DATA SYSTEM (VIRADS) TO PREDICT THE PATHOLOGICAL RESPONSE IN MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIBC): AN ANALYSIS OF THE PURE-01 COHORT
6. PD36-04 UTILITY OF PRE- AND POST-PEMBROLIZUMAB VESICAL IMAGING – REPORTING AND DATA SYSTEM (VIRADS) TO PREDICT THE PATHOLOGICAL RESPONSE IN MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIBC): AN ANALYSIS OF THE PURE-01 COHORT
7. MP58-08 CONCORDANCE OF RENAL SINUS OR CALYCES INVASION BETWEEN PREOPERATIVE IMAGING AND FINAL PATHOLOGY AFTER SURGERY FOR KIDNEY CANCER
8. Clinical Outcomes in Clinical N0 Squamous Cell Carcinoma of the Penis According to Nodal Management: Early, Delayed or Selective (following Dynamic Sentinel Node Biopsy) Inguinal Lymph-Node Dissection
9. MP56-02 NEOADJUVANT PEMBROLIZUMAB MAY RESULT IN LONG-TERM OUTCOME IMPROVEMENT IN BIOMARKER-UNSELECTED PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC): UPDATED RESULTS FROM PURE-01
10. PD40-10 FORMAL VALIDATION AT FINAL PATHOLOGY AFTER RADICAL NEHRECTOMY OF NEPHROMETRY SCORES: DISCORDANCE RATES AND OVERTREATMENT RISK
11. PD40-10 FORMAL VALIDATION AT FINAL PATHOLOGY AFTER RADICAL NEHRECTOMY OF NEPHROMETRY SCORES: DISCORDANCE RATES AND OVERTREATMENT RISK
12. MP56-02 NEOADJUVANT PEMBROLIZUMAB MAY RESULT IN LONG-TERM OUTCOME IMPROVEMENT IN BIOMARKER-UNSELECTED PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC): UPDATED RESULTS FROM PURE-01
13. MP47-09 THE ADDED VALUE OF HISTOLOGICAL SUBTYPE IN THE PREDICTION OF ONCOLOGIC OUTCOMES IN PATIENTS WITH NON-METASTATIC PAPILLARY RENAL CELL CARCINOMA
14. PD53-09 CLINICAL OUTCOMES IN CLINICAL N0 (CN0) SQUAMOUS CELL CARCINOMA (SCC) OF THE PENIS ACCORDING TO NODAL MANAGEMENT: EARLY, DELAYED OR SELECTIVE (FOLLOWING DYNAMIC SENTINEL NODE BIOPSY - DSNB) INGUINAL LYMPH-NODE DISSECTION (ILND)
15. PD53-09 CLINICAL OUTCOMES IN CLINICAL N0 (CN0) SQUAMOUS CELL CARCINOMA (SCC) OF THE PENIS ACCORDING TO NODAL MANAGEMENT: EARLY, DELAYED OR SELECTIVE (FOLLOWING DYNAMIC SENTINEL NODE BIOPSY - DSNB) INGUINAL LYMPH-NODE DISSECTION (ILND)
16. Reply by Authors
17. PD42-03 ASSOCIATION OF PATHOLOGIC RESPONSE TO NEOADJUVANT PEMBROLIZUMAB WITH TUMOR SUBTYPE FROM THE PURE01 STUDY
18. PD42-03 ASSOCIATION OF PATHOLOGIC RESPONSE TO NEOADJUVANT PEMBROLIZUMAB WITH TUMOR SUBTYPE FROM THE PURE01 STUDY
19. Reply by Authors
20. PD47-09 FIRST SURVIVAL OUTCOMES AND ADDITIONAL SECONDARY ANALYSES FROM PURE-01: PEMBROLIZUMAB (PEMBRO) BEFORE RADICAL CYSTECTOMY (RC) IN MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA (MIBC)
21. PD47-09 FIRST SURVIVAL OUTCOMES AND ADDITIONAL SECONDARY ANALYSES FROM PURE-01: PEMBROLIZUMAB (PEMBRO) BEFORE RADICAL CYSTECTOMY (RC) IN MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA (MIBC)
22. Persistent CD30 Expression by Embryonal Carcinoma in the Treatment Time Course: Prognostic Significance of a Worthwhile Target for Personalized Treatment
23. MP34-13 NEOADJUVANT SORAFENIB, GEMCITABINE, AND CISPLATIN (SGC) FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIUBC): FINAL RESULTS AND TRANSLATIONAL FINDINGS OF AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY
24. PD11-11 INTERIM RESULTS FROM PURE-01: A PHASE 2, OPEN-LABEL STUDY OF NEOADJUVANT PEMBROLIZUMAB (PEMBRO) BEFORE RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA (MIUC)
25. Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center
26. MP34-13 NEOADJUVANT SORAFENIB, GEMCITABINE, AND CISPLATIN (SGC) FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIUBC): FINAL RESULTS AND TRANSLATIONAL FINDINGS OF AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY.
27. PD41-02 A NEW PROPOSAL FOR T1, HIGH GRADE (HG) BLADDER CANCER (BCA) MICRO-STAGING DEFINITION
28. MP66-20 SIURO-PRIAS-ITA PROJECT: FIVE YEAR EXPERIENCE ON ACTIVE SURVEILLANCE
29. MP50-16 A PANEL OF TISSUE BIOMARKERS EXPRESSION TO ENHANCE PROGNOSTIC STRATIFICATION IN LOCALLY-ADVANCED AND METASTATIC UROTHELIAL CANCERS (UC) UNDERGOING PERI-OPERATIVE AND FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
30. Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration
31. 936 PERSISTENCE OF CD30 EXPRESSION BY EMBRYONAL CARCINOMA (EC) IN THE TREATMENT TIME COURSE. A RETROSPECTIVE SERIES OF MULTI-RELAPSING GERM-CELL TUMORS (GCT)
32. 708 THE CHARACTERISTICS OF INGUINAL LYMPH NODES MAY PREDICT PELVIC LYMPH NODES INVOLVEMENT IN PENILE CANCER: A SINGLE-INSTITUTIONAL EXPERIENCE
33. 709 POSITIVE NODE RATIO AND TOTAL NUMBER OF POSITIVE NODES MAY PREDICT RECURRENCE IN EARLY STAGE NON-SEMINOMATOUS GERM-CELL TUMOURS UNDERGOING PRIMARY RETROPERITONEAL LYMPH-NODE DISSECTION
34. 751 EARLY RESULTS OF THE PILOT STUDY WITH THE ANTI-EPIDERMAL GROWTH-FACTOR RECEPTOR (EGFR) MONOCLONAL ANTIBODY PANITUMUMAB IN PATIENTS (PTS) WITH MULTI-RELAPSED OR REFRACTORY SQUAMOUS CELL CARCINOMA (SCC) OF THE PENIS
35. MP66-20 SIURO-PRIAS-ITA PROJECT: FIVE YEAR EXPERIENCE ON ACTIVE SURVEILLANCE
36. PD41-02 A NEW PROPOSAL FOR T1, HIGH GRADE (HG) BLADDER CANCER (BCA) MICRO-STAGING DEFINITION
37. MP50-16 A PANEL OF TISSUE BIOMARKERS EXPRESSION TO ENHANCE PROGNOSTIC STRATIFICATION IN LOCALLY-ADVANCED AND METASTATIC UROTHELIAL CANCERS (UC) UNDERGOING PERI-OPERATIVE AND FIRST-LINE PLATINUM-BASED CHEMOTHERAPY.
38. The Relationship between Characteristics of Inguinal Lymph Nodes and Pelvic Lymph Node Involvement in Penile Squamous Cell Carcinoma: A Single Institution Experience
39. Persistent CD30 Expression by Embryonal Carcinoma in the Treatment Time Course: Prognostic Significance of a Worthwhile Target for Personalized Treatment
40. 942 THE RELATIONSHIP BETWEEN LYMPH-NODE DENSITY AND CANCER-SPECIFIC SURVIVAL IN A CONTEMPORARY SERIES OF PATIENTS WITH PENILE CANCER
41. 708 THE CHARACTERISTICS OF INGUINAL LYMPH NODES MAY PREDICT PELVIC LYMPH NODES INVOLVEMENT IN PENILE CANCER: A SINGLE-INSTITUTIONAL EXPERIENCE
42. 751 EARLY RESULTS OF THE PILOT STUDY WITH THE ANTI-EPIDERMAL GROWTH-FACTOR RECEPTOR (EGFR) MONOCLONAL ANTIBODY PANITUMUMAB IN PATIENTS (PTS) WITH MULTI-RELAPSED OR REFRACTORY SQUAMOUS CELL CARCINOMA (SCC) OF THE PENIS
43. 709 POSITIVE NODE RATIO AND TOTAL NUMBER OF POSITIVE NODES MAY PREDICT RECURRENCE IN EARLY STAGE NON-SEMINOMATOUS GERM-CELL TUMOURS UNDERGOING PRIMARY RETROPERITONEAL LYMPH-NODE DISSECTION
44. 936 PERSISTENCE OF CD30 EXPRESSION BY EMBRYONAL CARCINOMA (EC) IN THE TREATMENT TIME COURSE. A RETROSPECTIVE SERIES OF MULTI-RELAPSING GERM-CELL TUMORS (GCT)
45. Concordance and Prediction Ability of Original and Reviewed Vascular Invasion and Other Prognostic Parameters of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors After Retroperitoneal Lymph Node Dissection
46. CENTRALISED RE-ASSESSMENT OF VASCULAR INVASION IN CLINICAL STAGE I (CS I) NON-SEMINOMATOUS GERM-CELL TESTICULAR TUMOURS (NSGCTTS) SUBMITTED TO PRIMARY RETROPERITONEAL LYMPH-NODE DISSECTION (RPLND): CLINICAL IMPLICATIONS
47. Long-Term Followup and Clinical Characteristics of Testicular Leydig Cell Tumor: Experience With 24 Cases
48. CENTRALISED RE-ASSESSMENT OF VASCULAR INVASION IN CLINICAL STAGE I (CS I) NON-SEMINOMATOUS GERM-CELL TESTICULAR TUMOURS (NSGCTTS) SUBMITTED TO PRIMARY RETROPERITONEAL LYMPH-NODE DISSECTION (RPLND): CLINICAL IMPLICATIONS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.